Review of CMS’ coverage with evidence development program exposes a need to improve program transparency and clarify requirements and timetables for reporting to improve access to novel therapies.
David J. Slotwiner, MD
Advertisement
Articles by David J. Slotwiner, MD
Advertisement
Latest Updated Articles
- Coverage With Evidence Development: Where Are We Now?
April 7th 2022
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the FDA's Peptide Reversal
2
Moderna, Merck mRNA Cancer Vaccine Succeeds in Late-Stage Trial
3
FDA Approves First Orexin Agonist for Narcolepsy Type 1
4
Student Mental Health, Success Tied to Future Health and Affordability
5